NCT00020254View on ClinicalTrials.gov

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2000

Primary Completion Date

October 31, 2004

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

aldesleukin

BIOLOGICAL

recombinant fowlpox-prostate specific antigen vaccine

BIOLOGICAL

recombinant vaccinia prostate-specific antigen vaccine

BIOLOGICAL

recombinant vaccinia-B7.1 vaccine

BIOLOGICAL

sargramostim

DRUG

nilutamide

Trial Locations (1)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00020254 - Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter